Abstract
The effect of a single oral dose of loxiglumide, a cholecystokinin antagonist, on postprandial gallbladder contraction and on gastric emptying was evaluated in humans. Following a 12-hr fasting period, two tablets of loxiglumide (400 mg each) or placebo was administered on different days, in random order and in a double-blind fashion to 10 healthy volunteers 15 min before the ingestion of a 1050-kcal standard meal. Gallbladder and antral volumes were measured by real-time ultrasonography in basal conditions and at fixed time intervals after the meal. Oral loxiglumide administration was followed by a total inhibition of the gallbladder contraction for 60 min after the end of the meal ingestion. Thereafter, up to the end of the study period, gallbladder volume was larger than that of the placebo study (at 300 min after the meal 2.7±1.6 ml after placebo and 8.2±3.5 ml after loxiglumide; P<0.008). No difference between placebo and loxiglumide was found in the antral volumes at any time interval (postprandial 63.5±16.5 ml after placebo and 59.4±24 ml after loxiglumide; at 300 min after the meal 20.8±13.3 ml after placebo and 18.9±9.5 ml after loxiglumide). In conclusion, a single oral dose of loxiglumide at the dose of 800 mg can inhibit postprandial gallbladder contraction without affecting gastric emptying. It would therefore appear that in man endogenous CCK, released after a solid-liquid, caloric, nutrient-balanced meal, plays a major role in the contraction of the gallbladder but does not affect gastric emptying.
Similar content being viewed by others
References
Peikin SR, Costenbader CL, Gardner JD: Actions of derivatives of cyclic nucleotides on dispersed acini from guinea pig pancreas. J Biol Chem 254:5321–5327, 1979
Jensen RT, Jones SW, Gardner JD: Structure-function studies ofN-acyl derivatives of tryptophan that function as specific cholecystokinin receptor antagonists. Biochim Biophys Acta 761:269–277, 1983
Jensen RT, Murphy RB, Trampota M, Schneider LH, Jones SW, Howard JM, Gardner JD: Proglumide analogues: Potent cholecystokinin receptor antagonists. Am J Physiol 249:G214-G220, 1985
Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapely EO, Goetz MA, Albers-Schonberg G, Patchett AA, Liesch JM, Hensen OD, Springer JP: A potent non peptide cholecystokinin antagonist selective for peripheral tissue isolated fromAspergillus alliaceus. Science 230:177–179, 1985
Spanarkel M, Martinez J, Briet C, Jensen RT, Gardner JD: Cholecystokinin-27-32-amide. A member of a new class of cholecystokinin receptor antagonists. J Biol Chem 258:G746-G749, 1983
Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA: Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneim Forsch/Drug Res 37(I):703–707, 1987
Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L: Anticholecystokinin activities of loxiglumide. Arzneim Forsch/Drug Res 37 (II):1168–1171, 1987
Bolondi L, Bortolotti M, Santi V, Calletti T, Gaiani S, Labó G: Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology 89:752–759, 1985
Braverman DZ, Johnson ML, Kern F: Effects of pregnancy and contraceptive steroids on gallbladder function. N Engl J Med 302:362–364, 1980
Everson GT, Braverman DZ, Johnson ML, Kern F: A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology 79:40–46, 1980
Lilja P, Fagan CJ, Wiener I, Inoue K, Watson LC, Rayford PL, Thompson JC: Infusion of pure cholecystokinin in humans. Correlations between plasma concentrations of cholecystokinin and gallbladder size. Gastroenterology 83:256–261, 1982
Gullo L, Bolondi L, Priori P, Casanova P, Labó G: Inhibitory effect of atropine on cholecystokinin-induced gallbladder contraction in man. Digestion 29:209–213, 1984
Isaacs PET, Ladas S, Forgacs IC, Dowling RH, Ellam SV, Adrian TE, Bloom SR: Comparison of effects of ingested medium- and long-chain triglyceride on gallbladder volume and release of cholecystokinin and other gut peptides. Dig Dis Sci 32:481–486, 1987
Phaosawasdi K, Fisher RS: Hormonal effects on the pylorus. Am J Physiol 243:330–335, 1982
Chey WY, Hitanant S, Hendricks J, Lorber SH: Effect of secretin and cholecystokinin on gastric emptying and gastric secretion in man. Gastroenterology 58:820–827, 1970
Valenzuela JE, Defilippi C: Inhibition of gastric emptying in humans by secretin, the octapeptide of cholecystokinin, and intraduodenal fat. Gastroenterology 81:898–902, 1981
Liddle RA, Morita ET, Conrad CK, Williams JA: Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 77:992–996, 1986
Kleibeuker JH, Beekhuis H, Jansen JB, Piers DA, Lamers CB: Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin Invest 18:173–177, 1988
Scarpignato C, Zimbaro G, Vitulo F, Bertaccini G: Caerulein delays gastric emptying of solids in man. Arch Int Pharmacodyn Ther 249:98–105, 1981
Meyer B, Beglinger C, Zach D, Rovati L, Setnikar I, Stalder GA: Cholecystokinin (CCK) is a physiological regulator of gastric emptying in man. Gastroenterology 94:A301, 1988
Fried M, Lochner C, Erlacher U, Beglinger C, Jansen J, Lamers C, Stalder GA: Role of CCK in the regulation of gastric emptying and pancreatic secretion in man. Gastroenterology 96:A159, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corazziari, E., Ricci, R., Biliotti, D. et al. Oral administration of loxiglumide (CCK antagonist) inhibits postprandial gallbladder contraction without affecting gastric emptying. Digest Dis Sci 35, 50–54 (1990). https://doi.org/10.1007/BF01537222
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01537222